Summed rest score in gated myocardial perfusion imaging is a good predicator for treatment‑related cardiotoxicity after anthracycline chemotherapy in patients with diffuse large B‑cell lymphoma

Yang, Lin; Wang, Jianfeng; Xu, Min; Qiu, Chao; Xu, Peng; Shang, Limei; He, Ben; Wang, Fei; Yue, Yanhua; Guo, Yanting; Li, Feng; Dong, Weimin; Xie, Xian-Jin; Wang, Yuetao; Gu, Weiying

doi:10.3892/ol.2020.12194

Cited by 3 publications

(2 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Whereas the utility of perfusion-based imaging and myocardial blood flow quantitation for the detection of sub-clinical or early AIC has been studied in several small trials, additional research is needed to bring the evidence to the level of routine clinical utility. In particular, PET-derived myocardial blood flow has been examined as a potential marker of patients who may be at increased risk for AIC ( 157 , 158 ). Whether changes in myocardial blood flow metrics are a sign of early cardiac stress or indicative of irreversible toxicity in response to anthracyclines require further scrutiny ( 157 ).…”

Section: Need For Improved Cardiac Imaging Approaches In the Context ...mentioning

confidence: 99%

Anthracycline-induced cardiotoxicity: From pathobiology to identification of molecular targets for nuclear imaging

Jong

Pinney

Packard

2022

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

Anthracyclines are a widely used class of chemotherapy in pediatric and adult cancers, however, their use is hampered by the development of cardiotoxic side-effects and ensuing complications, primarily heart failure. Clinically used imaging modalities to screen for cardiotoxicity are mostly echocardiography and occasionally cardiac magnetic resonance imaging. However, the assessment of diastolic and global or segmental systolic function may not be sensitive to detect subclinical or early stages of cardiotoxicity. Multiple studies have scrutinized molecular nuclear imaging strategies to improve the detection of anthracycline-induced cardiotoxicity. Anthracyclines can activate all forms of cell death in cardiomyocytes. Injury mechanisms associated with anthracycline usage include apoptosis, necrosis, autophagy, ferroptosis, pyroptosis, reactive oxygen species, mitochondrial dysfunction, as well as cardiac fibrosis and perturbation in sympathetic drive and myocardial blood flow; some of which have been targeted using nuclear probes. This review retraces the pathobiology of anthracycline-induced cardiac injury, details the evidence to date supporting a molecular nuclear imaging strategy, explores disease mechanisms which have not yet been targeted, and proposes a clinical strategy incorporating molecular imaging to improve patient management.

show abstract

Section: Need For Improved Cardiac Imaging Approaches In the Context ...mentioning

confidence: 99%

Anthracycline-induced cardiotoxicity: From pathobiology to identification of molecular targets for nuclear imaging

Jong

Pinney

Packard

2022

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

show abstract

“…Multiple studies have been performed to define the best approach to detect early and possibly reversible effects of cardiac damage [1][2][3][4][5][6][7][8]. The most common surveillance tests to detect abnormalities in left ejection ventricular fraction (LVVF) are two-dimensional Echocardiogram (ECHO) and radionuclide ventriculography (RNV); other tests as magnetic resonance imagen and positron-emission tomography have been proposed, but these are very expensive.…”

Section: Introductionmentioning

confidence: 99%

Untitled

2023

IJCMCR

View full text Add to dashboard Cite

Cardiac toxicity associated with oncology drugs, is a known risk, although multiple studies has been performed to detect this problem in an early stage, no definitive results has been achieved. We conducted a clinical study in a large number of patients with a longer follow-up, to evaluate if surveillance tests, such as 2D echocardiogram (ECHO) and radionuclide ventriculography (RNV) can detected early cardiac damage in patients who received anthracycline-based chemotherapy. We conducted a cohort clinical study in 3073 patients with pathological confirmed of diffuse large B-cell lymphoma who had a complete response with a longer follow-up: 18. (range 6.8 to 32.3) years: the mentioned test was performed periodically: every 6 months the first 5 years, an annually from 5 years until relapse, death from any cause or last of follow-up, or the presence of congestive heart failure. Asymptomatic abnormalities in surveillance studies, without clinical and radiological evidence of cardiac damage were observed in 58 cases (1.21%); none of these patients developed clinical evidence of cardiac damage; and eight patients developed clinical and radiology evident changes of heart failure, neither of they showed previous abnormalities in surveillance studies. Multivariate analysis did no show any statistically difference, even in patients whose received > 450 mg/m2. The use of surveillance studies did not predict early cardiac damage and will not be used as surveillance tests. Now resources will be developed, because the risk of cardiac damage secondary to anthracyclines remains constant.

show abstract

Cardiac toxicity secondary to anthracycline treatment in diffuse large B-cell lymphoma

Aviles,

Cleto

2023

JCCR

View full text Add to dashboard Cite

Background: Cardiac toxicity associated with oncology drugs, is a known risk, although multiple studies has been performed to detect this problem in an early stage, no definitive results has been achieved. We conducted a clinical study in a large number of patients with a longer follow-up, to evaluate if surveillance tests, such as 2D echocardiogram (ECHO) and radionuclide ventriculography (RNV) can detected early cardiac damage in patients who received anthracycline-based chemotherapy. Patients and methods: We conducted a cohort clinical study in 3073 patients with pathological confirmed of diffuse large B-cell lymphoma that had a complete response with a longer follow-up: 18. (Range 6.8 to 32.3) years: the mentioned test were performed periodically: every 6months the first 5years, an annually from 5years until relapse, death from any cause or last of follow-up, or the presence of congestive heart failure. Results: Asymptomatic abnormalities in surveillance studies, without clinical and radiological evidence of cardiac damage were observed in 58 cases (1.21%); none of these patients developed clinical evidence of cardiac damage; and eight patients developed clinical and radiology evident changes of heart failure, neither of they showed previous abnormalities in surveillance studies. Multivariate analysis did not show any statistically difference, even in patients whose received > 450mg/m2. Conclusion: The use of surveillance studies did not predict early cardiac damage and will not be used as surveillance tests. Now resources will be developed, because the risk of cardiac damage secondary to anthracyclines remains constant.

show abstract

Summed rest score in gated myocardial perfusion imaging is a good predicator for treatment‑related cardiotoxicity after anthracycline chemotherapy in patients with diffuse large B‑cell lymphoma

Cited by 3 publications

References 54 publications

Anthracycline-induced cardiotoxicity: From pathobiology to identification of molecular targets for nuclear imaging

Anthracycline-induced cardiotoxicity: From pathobiology to identification of molecular targets for nuclear imaging

Untitled

Cardiac toxicity secondary to anthracycline treatment in diffuse large B-cell lymphoma

Contact Info

Product

Resources

About